Cinnamic acid derivatives as anticancer agents-A review

Current Medicinal Chemistry

Volumn 18, Issue 11, 2011, Pages 1672-1703

  De, P ^a,b   Baltas, M ^a,b   Bedos Belval, F ^a,b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b CNRS   (France)

Author keywords

Anticancer agents; Caffeic acid; Cinnamic acid; Cinnamic hydrazide; Cinnamide; Cinnamoyl ester

Indexed keywords

2 DEACETOXYTAXININE J; 4 [3' (1 ADAMANTYL) 4' HYDROXYPHENYL] 3 CHLOROCINNAMIC ACID; 4 CHLOROHOWIINOL A; 4 CYANOPHENYL 3,4 METHYLENEDIOXYCINNAMATE; ACRONINE; ANTHRAMYCIN; CAFFEIC ACID; CAFFEIC ACID PHENETHYL ESTER; CAMPTOTHECIN; CHLOROGENIC ACID; CINNAMIC ACID; CINNAMIC ACID DERIVATIVE; CINNAMOATE; CINNAMOYLRESERPINE; CKD 731; DISTAMYCIN A; DUOCARMYCIN A; ELLAGIC ACID; FERULIC ACID; FUMAGILLOL; FUMAGILLOL CHLOROACETYLCARBAMATE; GHM 10; GINSENOSIDE RG 1; HOWIINOL A; IMATINIB; METHYL 3,4 DIHYDROXYCINNAMATE; PANOBINOSTAT; PNU 157911; RACHELMYCIN; RESCINNAMATE; ROSMARINIC ACID; TANSHINONE IIA; TAXUYUNNANINE C; TPY 835; U 77 863; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CHRONIC MYELOID LEUKEMIA; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NEOPLASM; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TONGUE TUMOR;

ANTINEOPLASTIC AGENTS; CINNAMATES; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79955676741     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795471347     Document Type: Review

References (183)

1. Hoskins, J.A. The occurrence, metabolism and toxicity of cinnamic acid and related compounds. J. Appl. Toxicol., 1984, 4, 283-292. (Pubitemid 15152078)
2. Thimann, K.V. The auxins. In: Son, M.B. (ed.) Physiology of plant growth and development. 1969, McGrew-Hill, London, pp 2-45.
3. Epifano, F.; Curini, M.; Genovese, S.; Blaskovich, M.; Hamilton, A.; Sebti, S.M. Prenyloxyphenylpropanoids as novel lead compounds for the selective inhibition of geranylgeranyl transferase I. Bioorg. Med. Chem. Lett., 2007, 17(9), 2639-2642a).
4. Kroon, P.A.; Williamson, G. Hydroxycinnamates in plants and food. J. Sci. Food. Agri., 1999, 79, 355-361b).
5. Prager, R.H.; Thregold, H.M. Some neutral constituents of Acronychia baueri. Aust. J. Chem., 1966, 19, 451-454c).
6. a) Boerjan, W.; Ralph, J.; Baucher, M. Lignin biosynthesis. Annu. Rev. Plant Biol., 2003, 54, 519-546. (Pubitemid 37400004)
7. b) Humphreys, J.M.; Chapple, C.; Rewriting the lignin roadmap. Curr. Opin. Plant Biol., 2002, 5, 224-229. (Pubitemid 34452069)
8. b) Whetten, R.W.; Mackay, J.J.; Sederoff, R.R. Recent advances in understanding lignin biosynthesis. Ann. Rev. Plant Physiol. Plant Mol. Biol., 1998, 49, 585-609.
9. Freudenberg, K. Biosynthesis and constitution of lignin. Nature, 1959, 183, 1152-1155.
10. b) Zou, H. B.; Dong, S. Y.; Zhou, C. X.; Hu, L. H.; Wu, Y. H.; Li, H. B.; Gong, J. X.; Sun, L. L.; Wu, X. M.; Bai, H.; Fan, B. T.; Hao, X. J.; Stockigt, J.; Zhao, Y. Design, synthesis, and SAR analysis of cytotoxic sinapyl alcohol derivatives. Bioorg. Med. Chem., 2006, 14, 2060-2071. (Pubitemid 43199537)
11. Lee, K. H.; Huang, E.S.; Piantadosi, C.; Pagano, J.; Geissman, T.A. Cytotoxicity of Sesquiterpene Lactones, Cancer Res., 1971, 31, 1649-1654.
12. Drage, L. Cinnamic salts in the treatment of cancer. Br. Med. J., 1905, 1(2313), 927-928.
13. Li, Q.-F.; Shi, S.-L.; Liu, Q.-R.; Tang, J.; Song, J.; Liang, Y. Anticancer effects of Ginsenoside Rg1, cinnamic acid, and tanshinone in osteosacoma MG-63 cells: downregulation and cytoplasmic trafficking of Neucleophosmin. Int. J. Biochem. Cell Biol., 2008, 40, 1918-1929.
14. Shi, S.-L.; Li, Q.-F.; Liu, Q.-R.; Xu, D.-H.; Tang, J.; Song, J.; Liang, Y.; Zhao, Z.-L.; Yang, L.-M. J. Nuclear matrix protein, prohibitin, was downregulated and translocated from nucleus to cytoplasm during the differentiation of osteosarcoma MG-63 cells induced by ginsenoside Rg1, cinnamic acid, and tanshinone IIA (RCT). Cell. Biochem., 2009, 108, 926-934.
15. Ekmekcioglu, C.; Feyertag, J.; Marktl, W. Cinnamic acid inhibits proliferation and modulates brush border membrane enzyme activities in Caco-2 cells. Cancer Lett., 1998, 128, 137-144. (Pubitemid 28318727)
16. Liu, L.; Hudgins, W.R.; Shack, S.; Yin, M.Q.; Samid, D. Cinnamic acid: a natural product with potential use in cancer intervention. Int. J. Cancer, 1995, 62, 345-350.
17. Shiraishi,T.; Owada, M.K.; Tatsuka, M.; Yamashita, T.; Watanabe, K.; Kakunaga, T. Specific inhibitors of tyrosine-specific protein kinases: properties of 4-hydroxycinnanamide derivatives in vitro. Cancer Res., 1989, 49, 2374-2378. (Pubitemid 19125564)
18. Goldstein, J.L.; Brown, M.S. Regulation of the mevalonate pathway. Nature, 1990, 343, 425-430.
19. Stetler-Stevenson, W.G.; Krutzsch, H.C.; Liotta, L.A. Tissue inhibitor of metalloproteinase (TIMP 2): a new member of the metalloproteinase inhibitor family. J. Biol. Chem., 1988, 264, 17374-17378.
20. Nitzsche, A.; Tokalov, S.V.; Gutzeit, H.O.; Ludwig-Muller, J. Chemical and biological characterization of cinnamic acid derivatives from cell cultures of lavender (Lavandula officinalis) induced by stress and Jasmonic Acid. J. Agric. Food Chem., 2004, 52, 2915-2923.
21. Kang, N.J.; Lee, K.W.; Shin, B.J.; Jung, S.K.; Hwang, M. K.; M.Bode, A.; Heo, Y.- S.; Lee, H.J.; Dong, Z. Caffeic acid, a phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-induced COX-2 expression. Carcinogenesis, 2009, 30(2), 321-330.
22. An,K.P.; Athar, M.; Tang, X.; Katiyar, S.K.; Russo, J.; Beech, J.; Aszterbaum, M.; Kopelovich, L.; Epstein, E.H. Jr.; Mukhtar, H.; Bickers, D.R. Cyclooxygenase- 2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem. Photobiol., 2002, 76, 73-80.
23. Athar, M.; An, K.P.; Morel, K.D.; Kim, A.L.; Aszterbaum, M.; Longley, J.; Epstein, E.H. Jr.; Bickers, D.R. Ultraviolet B(UVB)-induced cox-2 expression in murine skin: an immunohistochemical study. Biochem. Biophys. Res. Commun., 2001, 280, 1042-1047. (Pubitemid 32924445)
24. Buckman, S.Y.; Gresham, A.; Hale, P.; Hruza, G.; Anast, J.; Masferrer, J.; Pentland, A.P. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis, 1998, 19, 723-729. (Pubitemid 28376760)
25. Grewe, M.; Trefzer, U.; Ballhorn, A.; Gyufko, K.; Henninger, H.; Krutmann, J. Analysis of the mechanism of ultraviolet (UV) B radiation-induced prostaglandin E2 synthesis by human epidermoid carcinoma cells. J. Invest. Dermatol., 1993, 101, 528-531. (Pubitemid 23285847)
26. Rundhaug, J.E.; Mikulec, C.; Pavone, A.; Fischer, S.M. A role for cyclooxygenase- 2 in ultraviolet light-induced skin carcinogenesis. Mol. Carcinog., 2007, 46, 692-698. (Pubitemid 47255189)
27. Verma, R.P.; Hansch, C. An approach towards the quantitative structureactivity relationships of caffeic acid and its derivatives. ChemBioChem, 2004, 5, 1188-1195. (Pubitemid 39297248)
28. a) Adamski, J.; Jakob, F. J. A guide to 17--hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol., 2001, 171, 1-4.
29. b) Mindnich, R.; Moller, G.; Adamski, J. The role of 17--hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol., 2004, 218, 7-20.
30. a) Penning, T.M.; Burczynski, M.E.; Jez, M.E.; Hung, C.F.; Lin, H.K.; Ma, H.; Moore, M.; Palackal, N.; Ratnam, K.; Human 3--hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex steroids. Biochem. J., 2000, 351, 67-77.
31. b) Penning, T.M. Hydroxysteroid dehydrogenases and prereceptor regulation of steroid hormone action. Hum. Reprod. Update, 2003, 9, 193-205. (Pubitemid 36827058)
32. Br-zc, P.; Golob, B.; Gomboc, N.; Rzner, T.L.; Gobec, S. Cinnamic acids as new inhibitors of 17--hydroxysteroid dehydrogenase type 5 (AKR1C3). Mol. Cell. Endocrind., 2006, 248, 233-235.
33. a) Sebti, S.M.; Hamilton, A.D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-tobedside translational studies. Oncogene, 2000, 19, 6584-6593. (Pubitemid 32197696)
34. b) Russo, P.; Loprevite, M.; Cesario, A.; Ardizzoni, A. Farnesylated proteins as anticancer drug targets: from laboratory to the clinic. Curr. Med. Chem. Anticancer Agents, 2004, 4, 123-138. (Pubitemid 38404688)
35. c) Pais, J.E.; Bowers, K.E.; Stoddard, A.K.; Fierke, C.A. A continuous fluorescent assay for protein prenyltransferases measuring diphosphate release. Anal. Biochem., 2005, 345, 302-311. (Pubitemid 41375960)
36. d) Appels, N.M.G.M.; Beijinen, J.H.; Schellens, J.H. Development of farnesyl transferase inhibitors: A review. Oncologist, 2005, 10, 565-578. (Pubitemid 41429120)
37. e) Basso, A.D.; Kirschmeier, P.; Bishop, W.R. Thematic review series: Lipid posttranslational modifications. Farnesyl transferase inhibitors. J. Lipid Res., 2006, 47, 15-31.
38. El Oualid, F.; Cohen, L.H.; Van der Marel, G.A.; Overhand, M. Inhibitors of protein: geranylgeranyl transferases. Curr. Med. Chem., 2006, 13, 2385-2427. (Pubitemid 44184644)
39. Ghisalberti, E.L. Propolis: A review. Bee World, 1979, 60, 59-84.
40. Marcucci, M.C. Propolis: chemical composition, biological properties and therapeutic activity. Apidologie, 1995, 26, 83-99.
41. Bankova, V.S.; de Castro, S.L.; Marcucci, M.C. Propolis: recent advances in chemistry and plant origin. Apidologie, 2000, 31, 3-15. (Pubitemid 30106313)
42. a) Banskota, A.H.; Tezuka, Y.; Kadota, S. Recent progress in pharmacological research of propolis. Phytother. Res., 2001, 15, 561-571. (Pubitemid 33021859)
43. b) Burdock, G.A. Review of the biological properties and toxicity of bee propolis (Propolis). Food Chem. Toxicol., 1998, 36, 347-363. (Pubitemid 28255348)
44. Akao, Y.; Maruyama, H.; Matsumoto, K.; Ohguchi, K.; Nishizawa, K.; Sakamoto, T.; Araki, Y.; Mishima, S.; Nozawa, Y. Cell growth inhibitory effect of cinnamic acid derivatives from propolis on human tumor cell lines. Bio. Pharm. Bull., 2003, 26(7), 1057-1059. (Pubitemid 41685442)
45. Matsuno, T.; Jung, S. K.; Matsumoto, Y.; Saito, M.; Morikawa, J. Preferential cytotoxicity to tumor cells of 3,5-diprenyl-4-hydroxycinnamic acid (Artepillin C) isolated from propolis. Anticancer Res., 1997, 17, 3565-3568. (Pubitemid 27522325)
46. Kimoto, T.; Aga, M.; Hino, K.; Koya-Miyata, S.; Yamamoto, Y.; Micallef, M.J.; Hanaya, T.; Arai, S.; Ikeda, M.; Kurimoto, M. Apoptosis of human leukemia cells induced by Artepillin C, an active ingredient of Brazilian propolis. Anticancer Res., 2001, 21, 221-228. (Pubitemid 32267646)
47. Kimoto, T.; Koya, S.; Hino, K.; Yamamoto, Y.; Nomura, Y.; Micallef, M. J.; Hanaya, T.; Arai, S.; Ikeda, M.; Kurimoto, M. Renal carcinogenesis induced by ferric nitrilotriacetate in mice, and protection from it by Brazilian propolis and Artepillin C. Pathol. Int., 2000, 50, 679-689.
48. Kimoto, T.; Koya, S.; Hino, K.; Micallef, M. J.; Hanaya, T.; Arai, S.; Ikeda, M.; Kurimoto, M. Pulmonary carcinogenesis induced by ferric nitrilotriacetate in mice and protection from it by Brazilian propolis and artepillin C. Virchows Arch., 2000, 438, 259-270. (Pubitemid 32247167)
49. Curini, M.; Epifano, F.; Genovese, S.; Marcotullio, M.C.; Menghini, L. 3-(4'- Geranyloxy-3'-Methoxyphenyl)-2-trans Propenoic acid: A novel promising cancer chemopreventive agent. Anticancer Agents Med. Chem., 2006, 6, 571-577. (Pubitemid 44697115)
50. Loris, R.; Hamelryck, T.; Bouckaert, J.; Wyns, L. Legume lectin structure. Biochim. Biophys. Acta, 1998, 1383 (1), 9-36. (Pubitemid 28130421)
51. Aoyagi, Y.; Masuko, N.; Ohkubo, S.; Kitade, M.; Nagai, K.; Okazaki, S.; Wierzba, K.; Terada, T.; Sugimoto, Y.; Yuji, Y. A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity. Cancer Sci., 2005, 96 (9), 614-619. (Pubitemid 41488425)
52. Mailand, N.; Falck, J.; Lukas, C. Syljuasen, R.G.; Welcker, M.; Bartek, J.; Lukas, J. Rapid destruction of human Cdc25A in response to DNA damage. Science, 2000, 288, 1425-1429. (Pubitemid 30366329)
53. Galaktionov, K.; Lee, A. K.; Eckstein, J.; Draetta, G.; Meckler, J.; Loda, M.; Beach, D. CDC25 phosphatases as potential human oncogenes. Science, 1995, 269, 1575-1577.
54. Gasparotto, D.; Maestro, R.; Piccinin, S.; Vukosavljevic, T.; Barzan, L.; Sulfaro, S.; Boiocchi, M. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res., 1997, 57, 2366-2368. (Pubitemid 27255891)
55. Kudo, Y.; Yasui, W.; Ue, T.; Yamamoto, S.; Yokozaki, H.; Nikai, H.; Tahara, E. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn. J. Cancer Res., 1997, 88, 947-952. (Pubitemid 27507390)
56. Wu, W.; Fan, Y.H.; Kemp, B.L.; Walsh, G.; Mao, L. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res., 1998, 58, 4082-4085. (Pubitemid 28440560)
57. Dixon, D.; Moyama, I.; King, M.J. Elevated expression of the cdc25A protein phosphatase in colon cancer. Exp. Cell Res., 1998, 240, 236-243. (Pubitemid 28371104)
58. Garner-Hamrick, P.A.; Fisher, C. Antisense phosphorothioate oligonucleotides specifically down-regulate cdc25B causing S-phase delay and persistent antiproliferative effects. Int. J. Cancer, 1998, 76, 720-728. (Pubitemid 28243947)
59. b) McClue, S.J.; Blake, D.; Clarke, R.; Cowan, A.; Cummings, L.; Fischer, P.M.; MacKenzie, M.; Melville, J.; Stewart, K.; Wang, S.; Zhelev, N.; Zheleva, D.; Lane, D.P. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer, 2002, 102, 463-468. (Pubitemid 35315999)
60. Dawson, M.I.; Xia, Z.; Liu, G.; Fontana, J.A.; Farhana, L.; Patel, B.B.; Arumugarajah, S.; Bhuiyan, M.; Zhang, X.-K.; Han, Y.-H.; Stallcup, W.B.; Fukushi, J.-i.; Mustelin, T.; Tautz, L.; Su, Y.; Harris, D. L.; Waleh, N.; Hobbs, P.D.; Jong, L.; Chao, W.-r.; Schiff, L.J.; Sani, B.P. An adamantylsubstituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: Effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity. J. Med. Chem., 2007, 50, 2622-2639. (Pubitemid 46896070)
61. Banskota, A.H.; Nagaoka, T.; Sumioka, L.Y.; Tezuka, Y.; Awale, S.; Midorikawa, K.; Matsushige, K.; Kadota, S. Antiproliferative activity of the Netherlands propolis and its active principles in cancer cell lines. J. Ethnopharmacol., 2002, 80, 67-73. (Pubitemid 34226641)
62. Koumenis, C.; Naczki, C. Method of using caffeic acid phenethyl ester and analogs thereof as radiation sensitizers. U.S.A. Patent 6,689,811 B1, February 10, 2004.
63. Liotta, L.A.; Steeg, P.; Stetler-Stevenson, W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 1991, 64, 327-36. (Pubitemid 121001258)
64. Birkedal-Hansen, H.; Moore, W.G.; Bodden, M.K.; Windsor, L.J.; Birkedal- Hansen, B.; DeCarlo, A.; Engler, J.A. Matrix metalloproteinases: a review. Crit. Rev. Oral. Biol. Med., 1993, 4, 197-250. (Pubitemid 23103292)
65. Hwang, H.J.; Park, H.J.; Chung, H.-J.; Min, H.-Y.; Park, E.-J.; Hong, J.-Y.; Lee, S.K. Inhibitory effects of caffeic acid phenethyl ester on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells. J. Nutr. Biochem., 2006, 17, 356-362.
66. Lee, K.W.; Kang, N.J.; Kim, J.H.; Lee, K.M.; Lee, D.E.; Hur, H.J.; Lee, H.J. Caffeic acid phenethyl ester inhibits invasion and expression of matrix metalloproteinase in SK-Hep1 human hepatocellular carcinoma cells by targeting nuclear factor kappa B. Genes Nutr., 2008, 2, 319-322. (Pubitemid 351447705)
67. Jung, J.W.; Cho, S.D.; Ahn, N.S.; Yang, S.R.; Park, J.S.; Jo, E.H.; Hwang, J.W.; Aruoma, O.I.; Lee, Y.S.; Kang, K.S.; Effects of the histone deacetylases inhibitors sodium butyrate and trichostatin A on the inhibition of gap junctional intercellular communication by H2O2- and 12- Otetradecanoylphorbol- 13-acetate in rat liver epithelial cells. Cancer Lett., 2006, 241, 301-308. (Pubitemid 44163042)
68. Natarajan, K.; Singh, S.; Burke Jr., T.R.; Grunberger, D.; Aggarwal, B.B. Caffeic acid phenetyl ester is a potent and specific inhibitor of activation of nuclear trascription factor NF-kappa B. Proc. Natl. Acad. Sci. USA, 1996, 93, 9090-9095. (Pubitemid 26282023)
69. Beg, A.A.; Baltimore, D. An essential role for NF--B in preventing TNF-ainduced cell death. Science, 1996, 274, 782-784.
70. Onori, P.; DeMorrow, S.; Gaudio, E.; Franchitto, A.; Mancinelli, R.; Venter, J.; Kopriva, S.; Ueno, Y.; Alvaro, D.; Savage, J.; Alpini, G.; Francis, H. Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF--B and induction of apoptosis. Int. J. Cancer., 2009, 125, 565-576.
71. Teitelbaum, S.L. Bone resorption by osteoclasts. Science, 2000, 289, 1504-1508.
72. Harris, N.L.; Watt, V.; MacLenachan, S.; Diehl, S.; Marsland, B.J.; Rincon, M.; Le Gros, G. Nuclear factor of activated T (NFAT) cells activity within CD4+ T cells is influenced by activation status and tissue localisation. Microbes Infect., 2006, 8(1), 232-237. (Pubitemid 43139311)
73. Wang, L.-C.; Chu, K.-H.; Liang, Y.-C.; Lin, Y.-L.; Chiang, B.-L. Caffeic acid phenethyl ester inhibits nuclear factor--B and protein kinase B signalling pathways and induces caspase-3 expression in primary human CD4+ T cells. Clin. Exper. Immunol., 2010, 160, 223-232.
74. Ang, E.S.M.; Pavlos, N.J.; Chai, L.Y.; Qi, M.; Cheng, T.S.; Steer, J.H.; Joyce, D.A.; Zheng, M.H.; Xu, J. Caffeic Acid Phenethyl Ester, an active component of honeybee propolis attenuates Osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF--B and NFAT activity. J. Cell. Physiol., 2009, 221, 642-649.
75. Jin, U.-H.; Song, K.-H.; Motomura, M.; Suzuki, I.; Gu, Y.-H.; Kang, Y.-J.; Moon, T.-C.; Kim, C.-H. Caffeic acid phenethyl ester induces mitochondriamediated apoptosis in human myeloid leukemia U937 cells. Mol. Cell Biochem., 2008, 310, 43-48.
76. Fels DR, Koumenis C The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol. Ther., 2006, 5, 723-728. (Pubitemid 44794028)
77. Oyadomari, S.; Mori, M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ., 2004, 11, 381-389. (Pubitemid 38489416)
78. Beltran-Ramirez, O.; Aleman-Lazarini, L.; Salcido-Neyoy, M.; Hernandez- Garcia, S.; Fattel-Fazenda, S.; Arce-Popoca, E.; Arellanes-Robledo, J.; Garcia- Roman, R.; Vazquez-Vazquez, P.; Sierra-Santoyo, A.; Villa-Trevino, S. Evidence that the anticarcinogenic effect of caffeic acid phenethyl ester in the resistant hepatocyte model involves modifications of cytochrome P450. Toxicol. Sci., 2008, 104(1), 100-106. (Pubitemid 351859032)
79. Wang, T.; Chen, L.-X.; Long, Y.; Wu, W.-M.; Wang R. DNA damage induced by caffeic acid phenyl ester in the presence of Cu(II) ions: Potential mechanism of its anticancer properties. Cancer lett., 2008, 263, 77-88. (Pubitemid 351424906)
80. Hadi, S.M.; Asad, S.F.; Singh, S.; Ahmad, A. Putative mechanism for anticancer and apoptosis-inducing properties of plant-derived polyphenolic compounds. IUBMB Life, 2000, 50, 167-171. (Pubitemid 32037930)
81. Kaufmann, S.H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res., 1989, 49, 5870-5878. (Pubitemid 19274139)
82. Rahman, A.; Shahabuddin, S.; Hadi, S.M.; Parish, J.H. Complexes involving quercetin, DNA and Cu(II). Carcinogenesis, 1990, 11, 2001-2003. (Pubitemid 20375946)
83. Nam, N.-H.; You, Y.-J.; Kim, Y.; Hong, D.-H.; Kim, H.-M.; Ahn, B. Z. Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity. Bioorg. Med. Chem. Lett., 2001, 11, 1173-1176. (Pubitemid 32406078)
84. Tanaka, T.; Kojima, T.; Kawamori, T.; Wang, A.; Suzui, M.; Okamoto K.; Mori, H. Inhibition of 4-nitroquinoline-1-oxide-induced rat tongue carcinogenesis by the naturally occurring plant phenolics caffeic, ellagic, chlorogenic and ferulic acids. Carcenogenesis, 1993, 14, 1321-1325. (Pubitemid 23229674)
85. Rodrigues, O.R.; Antonangelo, L., Yagi, N.; Minamoto, H.; Schmidt Jr., A.F.; Capelozzi, V.L.; Goldenberg, S.; Saldiva, P.H.N. Prognostic significance of argyrophilic nucleolar organizer region (AgNOR) in resected nonsmall cell lung cancer (NSCLC). Jap. J. Clinic. Oncol., 1997, 27, 298-304. (Pubitemid 127520817)
86. Kono, Y.; Shibata, H.; Kodama, Y.; Sawa, Y. The suppression of the Nnitrosating reaction by chlorogenic acid. Biochem. J., 1995, 312, 947-953. (Pubitemid 26006011)
87. Lee, W.J.; Zhu, B.T. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis, 2006, 27(2), 269-277. (Pubitemid 43159879)
88. Wall, M.E.; Wani, M.C.; Cook, C.E.; Palmer, K.H.; McPhail, A.T.; Sim, G.A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata. J. Am. Chem. Soc., 1966, 88, 3888-3890.
89. Gottlieb, J.A.; Guarino, A.M.; Call, J.B.; Oliverio, V.T.; Block, J.B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC- 100880). Cancer Chemother. Rep., Part 1, 1970, 54, 461-470.
90. Gottlieb, J.A.; Luce, J.K. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep., 1972, 56, 103-105.
91. Muggia, F.M.; Creaven, P.J.; Hansen, H.H.; Cohen, M.H.; Selawry, O.S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC- 100880): correlation with preclinical studies. Cancer. Chemother. Rep., 1972, 56, 515-21.
92. Moertel, C.G.; Schutt, A.J.; Reitemeier, R.J.; Hahn, R.G. Phase II studies of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 1972, 56, 95-101.
93. Schaeppi, U.; Fleishman, R.W.; Cooney, D.A. Toxicity of camptothecin (NSC-100880). Cancer Chemother. Rep., 1974, 5, 25-36.
94. Cao, Z.-S.; Mendoza, J.; Dejesus, A.; Giovanella, B. Synthesis and antitumor activity of alkenyl camptothecin esters. Acta Pharmacol. Sinica, 2005, 26 (2), 235-241. (Pubitemid 40203972)
95. Xu, C.-X.; He, J.-H. Anticancer effect of Howiinol A and its mechanism of action. J. Asian Nat. Prod. Res., 1999, 2(1), 1-19.
96. Chen, H.; Zhou, L. E.; Zhang, Y.J.; Yu, D.Q. Synthesis of (+) 8-O- Cinnamyl- p chlorogoniotriol and its analogues. Chin. Chem. Lett., 1999, 10(6), 449-452.
97. Svoboda, G.H.; Poore, G.A.; Simpson, P.J.; Boder, G.B. Alkaloids of Acronychia Baueri Schott I: Isolation of the alkaloids and a study of the antitumor and other biological properties of acronycine. J. Pharm. Sci., 1966, 55(8), 758-768.
98. Koch, M.; Tillequin, F.; Michel, S.; Hickman, J.; Pierre, A.; Leonce, S.; Pfeiffer, B.; Kraus-Berthier, L. Preparation of benzo[b]pyrano[3,2-h]acridin- 7-one cinnamate (acronycine) compounds as antitumor agents. U.S. Patent 2006/135545, June 22, 2006.
99. Greenblatt, M.; Bennett, W.P.; Hollstein, M.; Harris, C.C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res., 1994, 54, 4855-4878. (Pubitemid 24289415)
100. Salsbury, F.R. Jr.; Scarpinato, K.D.; King, S.B. Chemotherapeutic for indicing an MSH2-dependent apoptotic pathway. U.S. patent 2008/009979, March 05, 2009.
101. Folkman, J.; Shing, Y. Angiogenesis. J. Biol. Chem., 1992, 267, 10931-10934.
102. Folkman, J.Tumor angiogenesis. Adv. Cancer Res., 1985, 43, 175-203.
103. Kohn, E.C.; Liotta, L.A. Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res., 1995, 55, 1856-1862.
104. Ingber, D.; Fujita, T.; Kishimoto, S.; Sudo, K.; Kanamaru, T.; Brem, H.; Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature, 1990, 348, 555-557. (Pubitemid 120015110)
105. Marui, S.; Itoh, F.; Kozai, Y.; Sudo, K.; Kishimoto, S. Chemical Modification of Fumagillin. I. 6-O-Acyl, 6-O-Sulfonyl, 6-O-Alkyl and 6-O-(NSubstituted- carbamoyl)fumagillols. Chem. Pharm. Bull., 1992, 40, 96-101.
106. Sin, N.; Meng, L.; Wang, M.Q. W.; Wen, J.J.; Bornmann, W.G.; Crews, C.M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA, 1997, 94, 6099-6103. (Pubitemid 27270643)
107. Griffith, E.C.; Su, Z.; Turk, B.E.; Chen, S.; Chang, Y.-H.; Wu, Z.; Biemann, K.; Liu, J.O. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol., 1997, 4, 461-471. (Pubitemid 27288711)
108. Liu, S.; Widom, J.; Kemp, C.W.; Crews, C.M.; Clardy, J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science, 1998, 282, 1324-1327. (Pubitemid 28524496)
109. Han, C.K.; Ahn, S.K.; Choi, N.S.; Hong, R.K.; Moon, S.K.; Chun, H.S.; Lee, S.J.; Kim, J.W.; Hong, C.I.; Kim, D.; Yoon, J.K.; No, K.T. Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2. Bioorg. Med. Chem. Lett., 2000, 10, 39-43. (Pubitemid 30014666)
110. Schobert, R.; Kern, W.; Milius, W.; Ackermann, T.; Zoldakova, M. Synthesis of the first unnatural schisantherins and their effects in multidrug-resistant cancer cells. Tet. Lett., 2008, 49, 3359-3362.
111. Ueda, K.; Pastan, I.; Gottesman, M.M. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J. Biol. Chem., 1987, 262, 17432-17436. (Pubitemid 18032220)
112. Sulova, Z.; Mislovicova, D.; Gibalova, L.; Vajcnerova, Z.; Polakova, E.; Uhrik, B.; Tylkova, L.; Kovarova, A.; Sedlak, J.; Breier, A. Vincristineinduced overexpression of P-glycoprotein in L1210 cells is associated with remodeling of cell surface saccharides. J. Proteome Res., 2009, 8, 513-520.
113. Bai, J.; Kitabatake, M.; Toyoizumi, K.; Fu, L.; Zhang, S.; Dai, J.; Sakai, J.; Hirose, K.; Yamori, T.; Tomida, A.; Tsuruo, T.; Ando, M. Production of biologically active taxoids by a callus culture of Taxus cuspidata. J. Nat. Prod., 2004, 67, 58-63. (Pubitemid 38141312)
114. Hasegawa, T.; Bai, J.; Dai, J.; Bai, L.; Sakai, J.; Nishizawa, S.; Bai, Y.; Kikuchi, M.; Abe, M.; Yamori, T.; Tomida, A.; Tsuruo, T.; Hirose, K.; Ando, M. Synthesis and structure-activity relationships of taxuyunnanine C derivatives as multidrug resistance modulator in MDR cancer cells. Bioorg. Med. Chem. Lett., 2007, 17, 3722-3728. (Pubitemid 46898802)
115. Reddy, K.P.; Bid, H.K.; Nayak, V.L.; Chaudhary, P.; Chaturvedi, J.P.; Arya, K.R.; Konwar, R.; Narender, T. In vitro and in vivo anticancer activity of 2- deacetoxytaxinine J and synthesis of novel taxoids and their in vitro anticancer activity. Eur. J. Med. Chem., 2009, 44, 3947-3953.
116. Atsumi, T.; Sanjiki, T.; Kiyohara, T. Imidazole derivatives, their preparation and their pharmaceutical compositions. Eur. Patent, EP 0075629, April 04,1983.
117. Boudreau, L.H.; Picot, N.; Doiron, J.; Villebonnet, B.; Surette, M.E.; Robichauda, G.A.; Touaibia, M. Caffeoyl and cinnamoyl clusters with antiinflammatory and anti-cancer effects. Synthesis and structure-activity relationship. New J. Chem., 2009, 33, 1932-1940.
118. a) Avis, I. Hong, S.H.; Martinez, A.; Moody, T.; Choi, Y.H.; Trepel, J.; Das, R.; Jett, M.; Mulshine, J.L. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. The FASEB J., 2001, 15, 2007-2009.
119. b) Maccarrone, M.; Catani, M.V.; Agro, A. F.; Melino, G. Involvement of 5-lipoxygenase in programmed cell death of cancer cells. Cell Death Differ., 1997, 4(5), 396-402. (Pubitemid 127680674)
120. Lan-Hargest, H.-Y.; Weich, N. L. Preparation of --dicarbonyl compounds as inhibitors of histone deacetylase. Eur. Pat. Appl., 2001, EP 1216986 A2 20020626.
121. Br-z-c, P.; Kocbek, P.; Sova, M.; Kristl, J.; Martens, S.; Adamski, J.; Gobec, S. R-zner, T.L. Flavonoids and Cinnamic acid derivatives as inhibitors of 17--hydroxysteroid dehydrogenase type 1. Mol. Cell. Endocrin., 2009, 301, 229-234.
122. Welch, D.R.; Harper, D.E.; Yohem, K.H. U-77,863: a novel cinnamide isolated from Streptomyces griseoluteus that inhibits cancer invasion and metastasis. Clin. Exp. Mestastasis, 1993, 11, 201-212. (Pubitemid 23080163)
123. Cozzi, P.; Beria, I.; Biasoli, G.; Caldarelli, M.; Capolongo, L.; Geroni, C.; Mongelli, N. Novel phenyl nitrogen mustard and half-mustard derivatives of distamycin A. Bioorg. Med. Chem. Lett., 1997, 7, 2985-2990. (Pubitemid 27519572)
124. Cozzi, P.; Beria, I.; Biasoli, G.; Caldarelli, M.; Capolongo, L.; D'Alessio, R.; Geroni, C.; Mazzini, S.; Ragg, E.; Rossi, C.; Mongelli, N. Novel phenyl nitrogen mustard and half-mustard derivatives of amidino-modified distamycin. Bioorg. Med. Chem. Lett., 1997, 7, 2979-2984. (Pubitemid 27519571)
125. Cozzi, P.; Baraldi, P.G.; Beria, I.; Caldarelli, M.; Geroni, C.; Pennella, G.; Romagnoli, R. Cinnamoyl distamycin analogous derivatives, process for their preparation and their use as antitumor agents. U.S. Patent 6,596,845 B1, July 22, 2003.
126. Baraldi, P.G.; Beria, I.; Cozzi, P.; Geroni, C.; Espinosa, A.; Gallo, M.A.; Entrena, A.; Bingham, J.P.; Hartley, J.A. and Romagnoli, R. Cinnamoyl nitrogen mustard derivatives of pyrazole analogues of tallimustine modified at the amidino moiety: design, synthesis, molecular modeling and antitumor activity studies. Bioorg. Med. Chem., 2004, 12, 3911-3921. (Pubitemid 38798253)
127. b) Kohn, K.W.; Spears, C.L. Reaction of anthramycin with deoxyribonucleic acid. J. Mol. Biol., 1970, 51, 551-572.
128. c) Hurley, L.H.; Gairpla, C.; Zmijewski, M. Proposed structure of the anthramycin-DNA adduct. Biochem. Biophys. Acta, 1977, 475, 521-535.
129. d) Kaplan, D. J.; Hurley, L. H. Anthramycin binding to deoxyribonucleic acid-mytomycin C complexes: Evidence for druginduced DNA conformational change and cooperativity in mitomycin C binding. Biochemistry, 1981, 20, 7572-7580. (Pubitemid 12189300)
130. e) Thurston, D.E.; Bose, D.S.; Thomson, A.S.; Howard, P.W.; Leoni, A.; Croker, S.J.; Jenkins, T.C.; Neidle, S.; Hurley, L.H. Synthesis of sequence-selective C8-linked pyrrolo[ 2,1-c][1,4]benzodiazepine DNA interstrand cross-linking agents. J. Org. Chem., 1996, 61, 8141-8147. (Pubitemid 26400930)
131. b) Yasuzawa, T.; Iida, T.; Muroi, K.; Ichimura, M.; Takahashi, K.; Sano, H. Structures of duocarmycins, novel antitumor antibiotics produced by Streptomyces sp. Chem. Pharm. Bull., 1988, 36, 3728-3731.
132. c) Ichimura, M.; Muroi, K.; Asano, K.; Kawamoto, I.; Tomita, F.; Morimoto, M.; Nakano, H. DC-89A1, A new antibiotics from Streptomyces. J. Antibiot., 1988, 41, 1285-1288.
133. d) Ogawa, T.; Ichimura, M.; Katsumata, S.; Morimoto, M.; Takahashi, K. New antitumor antibiotics, duocarmycin B1 and B2. J. Antibiot., 1989, 42, 1299-1301.
134. e) Ichimura, M.; Ogawa, T.; Takahashi, K.; Kobayashi, E.; Kawamoto, I.; Yasuzawa, T.; Takahashi, I.; Nakano, H. Duocarmycin SA, A new antitumor antibiotic from Streptomyces sp. J. Antibiot., 1990, 43, 1037-1038.
135. f) Yasuzawa, T.; Saitoh, Y.; Ichimura, M.; Takahashi, I.; Sano, H. Structure of duocarmycin SA, a potent antitumor antibiotic. J. Antibiot., 1991, 44, 445- 447.
136. g) Ichimura, M.; Ogawa, T.; Katsumata, S.; Takahashi, K.; Takahashi, I.; Nakano, H. Duocarmycins, new antibiotics produced by Streptomyces; producing organisms and improved production. J. Antibiot., 1991, 44, 1045- 1053.
137. a) Boger, D.L.; Ishizaki, T.; Zarrinmayeh, H. Synthesis and preliminary evaluation of agents incorporating the pharmacophore of the duocarmycin/ pyrindamycin alkylation subunit: Identification of the CC- 1065/duocarmycin common pharmacophore. J. Org. Chem., 1990, 55, 4499- 4502.
138. b) Sugiyama, H.; Hosoda, M.; Saito, I.; Asai, A.; Saito, H. Covalent alkylation of DNA with duocarmycin A. Identification of abasic site structure. Tetrahedron Lett., 1990, 31, 7197-7200.
139. c) Boger, D.L.; Ishizaki, T.; Zarrinmayeh, H.; Munk, S.A.; Kitos, P.A.; Suntornwat, O. Duocarmycinpyrindamycin DNA alkylation properties and identification, synthesis, and evaluation of agents incorporating the pharmacophore of the duocarmycinpyrindamycin alkylation subunit. Identification of the CC-1065- duocarmycin common pharmacophore. J. Am. Chem. Soc., 1990, 112, 8961-8971.
140. d) Boger, D.L.; Ishizaki, T.; Zarrinmayeh, H. Isolation and characterization of the duocarmycin-adenine DNA adduct. J. Am. Chem. Soc., 1991, 113, 6645- 6649.
141. e) Sugiyama, H.; Ohmori, K.; Chan, K.L.; Hosoda, M.; Asai, A.; Saito, H.; Saito, I. A novel guanine N3 alkylation by antitumor antibiotic duocarmycin A. Tetrahedron Lett., 1993, 34, 2179-2182.
142. f) Boger, D.L.; Johnson, D.S.; Yun, W. (+)- and ent-(-)- Duocarmycin SA and (+)- and ent-(-)-NBoc- DSA DNA alkylation properties. Alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity of the enantiomeric agents. J. Am. Chem. Soc., 1994, 116, 1635-1656.
143. b) Martin, D.G.; Chidester, C.G.; Duchamp, D.J.; Mizsak S.A. Structure of CC-1065 (NSC- 298223), A new antitumor antibiotic. J. Antibiot., 1980, 33, 902-903. (Pubitemid 11231479)
144. c) Reynolds, V.L.; McGovren, J.P.; Hurley, L.H. The chemistry, mechanism of action and biological properties of CC- 1065, a potent antitumor antibiotic. J. Antibiot., 1986, 39, 319-334. (Pubitemid 16108752)
145. b) Reynolds, V.L.; Molineaux, I.J.; Kaplan, D.J.; Swensen, D.H.; Hurley, L.H. Reaction of the antitumor antibiotic CC-1065 with DNA. Location for the site of thermally induced strand breakage and analysis of DNA sequence specificity. Biochemistry, 1985, 24, 6228-6237. (Pubitemid 16197378)
146. c) Tang, M.S.; Lee, C.S.; Doisy, R.; Ross, L.; Needham-VanDevanter, D.R.; Hurley, L.H. Recognition and repair of the CC-1065 -(N3-adenine)-DNA adduct by the UVRABC nuclease. Biochemistry, 1988, 27, 893-901. (Pubitemid 18052984)
147. Gomi, K.; Kobayashi, E.; Miyoshi, K.; Ashizawa, T.; Okamoto, A.; Ogawa,
148. a) A number of reviews on the duocarmycins are available from the following: Boger, D. L. Duocarmycins: A new class of sequence selective DNA minor groove alkylating agents. Chemtracts: Org. Chem., 1991, 4, 329-349.
149. b) Boger, D.L. The duocarmycins: Synthetic and mechanistic studies. Acc. Chem. Res., 1995, 28, 20-29.
150. c) Boger, D.L.; Johnson, D.S. CC-1065 and the duocarmycins: Unraveling the keys to a new class of naturally derived DNA alkylating agents. Proc. Natl. Acad. Sci. USA, 1995, 92, 3642-3649.
151. d) Boger, D.L.; Johnson, D.S. CC-1065 and the duocarmycins: Understanding their biological function through mechanistic studies. Angew. Chem. Int. Ed., 1996, 35, 1438-1474. (Pubitemid 26310030)
152. Nagamura, S.; Asai, A.; Amishiro, N.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and antitumor activity of duocarmycin derivatives: A-ring pyrrole compounds bearing cinnamoyl groups. J. Med. Chem., 1997, 40, 972-979. (Pubitemid 27131628)
153. Gonnella, N.C.; Li, Y.C.; Zhang, X.; Paris, C.G. Bioactive conformation of a potent stromelysin inhibitor determined by X-nucleus filtered and multidimensional NMR spectroscopy. Bioorg. Med. Chem., 1997, 5(12), 2193-2201. (Pubitemid 28012607)
154. Zhang, L.; Zhang, J.; Fang, H.; Wang, Q.; Xu, W. Design, synthesis and preliminary evaluation of new cinnamoyl pyrrolidine derivatives as potent gelatinase inhibitors. Bioorg. Med. Chem., 2006, 14, 8286-8294. (Pubitemid 44667556)
155. Jordis, U.; Sauter, F.; Siddiqi, S.M. Synthesis of (1S,4S)-2-thia-5- azabicyclo[2.2.1]heptanes. Indian J. Chem. Sec. B, 1989, 28(4), 294-296.
156. Danziger, R.S. Aminopeptidase N in arterial hypertension. Heart Fail. Rev., 2008, 133, 293-298.
157. Shimizu, T.; Tani, K.; Hase, K.; Ogawa, H.; Huang, L.; Shinomiya, F.; Sone, S. CD13/aminopeptidase N-induced lymphocyte involvement in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum., 2002, 46, 2330-2338.
158. Sato, Y. Role of aminopeptidase in angiogenesis, Biol. Pharm. Bull. 2004, 27, 772-776. (Pubitemid 41701786)
159. Pardin, C.; Roy, I.; Chica, R.A.; Bonneil, E.; Thibault, P.; Lubell, W.D.; Pelletier, J.N.; Keillor, J.W. Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors. Biochemistry, 2009, 48, 3346-3353.
160. Davies, P.J.; Davies, D.R.; Levitzki, A.; Maxfield, F.R.; Milhaud, P.; Willingham, M.C.; Pastan, I.H. Transglutaminase is essential in receptormediated endocytosis of R2-macroglobulin and polypeptide hormones. Nature, 1980, 283, 162-167. (Pubitemid 10171126)
161. Fesus, L.; Thomazy, V.; Falus, A. Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett., 1987, 224, 104-108. (Pubitemid 17159992)
162. Birckbichler, P.J.; Orr, G.R.; Patterson, M.K.; Conway, E.; Carter, H.A.; Maxwell, M.D. Enhanced transglutaminase activity in transformed human lung fibroblast cells after exposure to sodium butyrate. Biochim. Biophys. Acta, 1983, 763, 27-34. (Pubitemid 13036115)
163. Marrano, C.; de Macédo, P.; Gagnon, P.; Lapierre, D.; Gravel, C.; Keillor, J.W. Synthesis and Evaluation of dipeptide-Bound 1,2,4-thiadiazoles as irreversible transglutaminase inhibitors. Bioorg. Med. Chem., 2001, 9, 3231-3241.
164. Pardin, C.; Pelletier, J.N.; Lubelle, W.D.; Keillor, J.W. Cinnamoyl inhibitors of tissue transglutaminase. J. Org. Chem., 2008, 73, 5766-5775.
165. Lesyk, R.; Vladzimirska, O.; Holota, S.; Zaprutko, L.; Gzella, A. New 5- substituted thiazolo[3,2-b][1,2,4]triazol-6-ones: Synthesis and anticancer evaluation. Eur. J. Med. Chem., 2007, 42, 641-648. (Pubitemid 46719491)
166. Levistzki, A.; Willingham, M.; Pastan, I.H. Evidence for participation of transglutaminase in receptor-mediated endocytosis. Proc. Natl. Acad. Sci. USA, 1980, 77, 2706-2710. (Pubitemid 10057904)
167. b) Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantariian, H.; Capedeville, R.; Ohno-Jones, S.; Sawyer, C.L. Efficacy and safety of a specific inhibitor of Bcr-Abl tyrosine kinase in chronicmyeloid leukemia. N. Eng. J. Med., 2001, 344, 1031-1037. (Pubitemid 32267972)
168. b) Hochhaus, A.; Kreil, S.; Corbin, A.S.; La Rosee, P.; Muller, M.C.; Lahaye, T.; Hanfstein, B.; Schoch, C.; Cross, N.C.U.; Berger, U.; Gschaidmeier, H.; Druker, B.J.; Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imanitib (STI-571) therapy. Leukemia, 2002, 11, 2190-2196. (Pubitemid 35331833)
169. Chang, S.; Yin, S.-L.; Wang, J.; Jing, Y.-K. Dong, J.-H. Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells. Molecules, 2009, 14, 4166-4179.
170. b) Bredereck, H.; Effenberger, F.; Bosch, H. Saureamid-Reaktionen, XLV. Untersuchungen uber die Reaktionsfahigkeit von Formamidinen, Dimethylformamid- diathylacetal (Amidacetal) und Bis-dimethyl-amino-methoxy-methan (Aminalester). Ber. Dtsch. Chem. Ges., 1964, 97, 3397-3406.
171. Ahmed, K.; Gorre, B.; Gadupudi, R.; Kokkanda, S.; Rajeinder Cinnamido- Pyrrolo[2,1-c][1,4]benzodiazepines as potential anticancer agents and process of the preparation thereof. Int. Patent, WO 2010/052732 A1, May 14, 2010.
172. Srivastava, V.; Srivastava, A.M.; Tiwari, A.K.; Srivastava, R.; Sharma, R.; Sharma, H.; Singh, V.K. Disubstituted 4(3H) quinazolones: A novel class of antitumor agents. Chem. Biol. Drug Des., 2009, 74, 297-301.
173. Burley, S.K.; David, P.R.; Lipscomb, W.N. Leucine aminopeptidase: bestatin inhibition and a model for enzyme-catalyzed peptide hydrolysis. Proc. Natl. Acad. Sci. USA, 1991, 88 (16), 6916-6920. (Pubitemid 21915060)
174. Liu, Y.; Shang, L.; Fang, H.; Zhu, H.; Mua, J.; Wang, Q.; Wang, X.; Yuan, Y.; Xu, W.; Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-l-aspartic acid as inhibitors of aminopeptidase N/CD13. Bioorg. Med. Chem., 2009, 17, 7398-7404.
175. Minucci, S. ; Pelicci, P.G. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature, 2006, 6, 38-44.
176. Cress, W.D.; Seto, E. Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol., 2000, 184, 1-16. (Pubitemid 30349623)
177. Marks, P.; Rifkind, R.A.; Richon, V.M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer, 2001, 1, 194-202. (Pubitemid 33741894)
178. Bhalla, K.N. Epigenetic and chromatinmodifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol., 2005, 23, 3971-3993. (Pubitemid 46218700)
179. Zhang, C.; Richon, V.; Ni, X.; Talpur, R.; Duvic, M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA incutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J. Invest. Dermatol., 2005, 125, 1045-1052.
180. Mann, B.S.; Johnson, J.R.; Cohen, M.H.; Justice, R.; Pazdur, R. FDA Approval summary: vorinostat for treatment of advanced primary cutaneous TCell lymphoma. Oncologist, 2007, 12, 1247-1252. (Pubitemid 350106355)
181. George, P.; Bali, P.; Annavarapu, S.; Scuto, A.; Fiskus, W.; Guo, F.; Sigua, C.; Sondarva, G.; Moscinski, L.; Atadja, P.; Bhalla, K. Combinationof the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor17-AAGis highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood, 2005, 105, 1768-1776. (Pubitemid 40223701)
182. Giles, F.; Fischer, T.; Cortes, J.; Garcia-Manero, G.; Beck, J.; Ravandi, F. Masson, E.; Rae, P.; Laird, G.; Sharma, S.; Kantarjian, H.; Dugan, M.; Albitar, M.; Bhalla, K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res., 2006, 12(15), 4628-4635. (Pubitemid 44297814)
183. b) De, P.; Baltas, M.; Lamoral-Theys, D.; Bruyere, C.; Kiss, R.; Bedos-Belval, F.; Saffon, N. Synthesis and anticancer activity evaluation of 2(4-alkoxyphenyl)cyclopropyl hydrazides and triazolo phthalazines. Bioorg. Med. Chem., 2010, 18, 2537-2548.